This is an elective module of the Biomarker Testing Navigation Certificate program. dives into the essential financial and business aspects crucial for any biomarker testing laboratory. It explores vital topics like cost analysis, prior authorization workflows, accurate billing and reimbursement, and effective financial planning. The module also examines the impact of regulatory and payer changes on laboratory sustainability and equips participants with practical skills needed to ensure effective economic stewardship of biomarker testing services.
Course topics include:
Cost analysis of testing
Prior authorization in biomarker testing
Billing and reimbursement
Budgeting and financial planning
Regulatory and payer considerations
Target Audience
Amanda Hanson, MS Director, Precision Medicine Spartanburg Regional Healthcare System Spartanburg, SC
CMLE Credit: 1.0Estimated Completion Time: 1 hourFormat: Online educational activity
Credit Designation Statement
ASCP designates this activity for a maximum of 1 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CMLE credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.
Method of ParticipationTo complete the activity and receive credit, the participant must complete the online activity. CMLE certificates will be provided online. Commercial Support This activity is supported by a sponsorship from AstraZeneca.
Instructions
To claim CMLE credit for the exercise, do the following:
Upon completion of this activity, you will be able to:
Analyze cost components of biomarker testing and identify optimization strategies.
Explain the workflow and requirements for biomarker test prior authorization.
Apply strategies to optimize biomarker test billing, reimbursement, and denial management.
Describe the foundational components of budgeting and financial planning in laboratory management.
Evaluate the impact of regulatory and payer changes on biomarker testing financial sustainability.